Review anchor
Tyrosine-protein kinase JAK2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
Evidence Snapshot
Tyrosine-protein kinase JAK2
CHEMBL2971
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Tyrosine-protein kinase JAK2 as ChEMBL target CHEMBL2971, mapped to UniProt O60674. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2971
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
O60674
Tyrosine-protein kinase JAK2
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Tyrosine-protein kinase JAK2 matters
Tyrosine-protein kinase JAK2 is reviewed as Tyrosine-protein kinase JAK2 (UniProt O60674); Tyrosine-protein kinase JAK2 shows approved-linked disease relevance led by Myelofibrosis. 5 more disease programs remain visible in the same review block.; 8 linked drugs keep this evidence frame grounded.; the current evidence base includes 53 approved drugs, 17524 compounds, and 1800 assays, with lead potency reaching pChEMBL 11.0.
Protein context
Tyrosine-protein kinase JAK2
Tyrosine-protein kinase JAK2 Sequence length is 1132 aa.
Review this target as Tyrosine-protein kinase JAK2, mapped to UniProt O60674. Sequence length is 1132 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt O60674
Protein
Disease context
Myelofibrosis
Tyrosine-protein kinase JAK2 shows approved-linked disease relevance led by Myelofibrosis. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include FEDRATINIB, FEDRATINIB HYDROCHLORIDE, LESTAURTINIB.
Start review with Myelofibrosis because it currently carries approved-linked support. Linked drugs include FEDRATINIB, FEDRATINIB HYDROCHLORIDE, LESTAURTINIB, MOMELOTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
8 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 53 approved drugs, 17524 compounds, and 1800 assays for this target. The dominant activity type is IC50. CHEMBL3665128 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL3665128 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
53 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Tyrosine-protein kinase JAK2 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt O60674, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why Myelofibrosis is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
17524
Total Compounds
1800
Total Assays
53
Approved Drugs
IC50: 19204.0, KI: 4638.0, EC50: 313.0, KD: 483.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3665128
|
11.0 | IC50 | — |
|
|
No preferred name
CHEMBL3665130
|
11.0 | IC50 | — |
|
|
No preferred name
CHEMBL5776613
|
10.9 | Ki | — |
|
|
No preferred name
CHEMBL5997591
|
10.9 | Ki | — |
|
|
No preferred name
CHEMBL6036273
|
10.9 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
MOMELOTINIB
CHEMBL1078178
|
2023 |
|
|
REPOTRECTINIB
CHEMBL4298138
|
2023 |
|
|
CRAVACITINIB
CHEMBL4596392
|
2022 |
|
|
PACRITINIB
CHEMBL2035187
|
2022 |
|
|
DEUCRAVACITINIB
CHEMBL4435170
|
2022 |
|
|
ABROCITINIB
CHEMBL3655081
|
2021 |
|
|
PRALSETINIB
CHEMBL4582651
|
2020 |
|
|
FILGOTINIB
CHEMBL3301607
|
2020 |
|
|
FEDRATINIB
CHEMBL1287853
|
2019 |
|
|
ENTRECTINIB
CHEMBL1983268
|
2019 |
|
|
UPADACITINIB
CHEMBL3622821
|
2019 |
|
|
PEFICITINIB
CHEMBL3137308
|
2019 |
|
|
LORLATINIB
CHEMBL3286830
|
2018 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
BRIGATINIB
CHEMBL3545311
|
2017 |
|
|
BARICITINIB
CHEMBL2105759
|
2017 |
|
|
CERITINIB
CHEMBL2403108
|
2014 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
TOFACITINIB
CHEMBL221959
|
2012 |
|
|
TOFACITINIB CITRATE
CHEMBL2103743
|
2012 |
|
|
PONATINIB
CHEMBL1171837
|
2012 |
|
|
RUXOLITINIB PHOSPHATE
CHEMBL1795071
|
2011 |
|
|
RUXOLITINIB
CHEMBL1789941
|
2011 |
|
|
CRIZOTINIB
CHEMBL601719
|
2011 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
|
|
DASATINIB
CHEMBL5416410
|
2006 |
Source Header